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Brucellosis is a chronic infectious disease caused by Brucella spp., a Gram-negative facultative intracellular pathogen that affects
humans and animals, leading to significant impact on public health and animal industry. Human brucellosis is considered themost
prevalent bacterial zoonosis in the world and is characterized by fever, weight loss, depression, hepato/splenomegaly, osteoarticular,
and genital infections. Relevant aspects of Brucella pathogenesis have been intensively investigated in culture cells and animal
models. The mouse is the animal model more commonly used to study chronic infection caused by Brucella. This model is most
frequently used to investigate specific pathogenic factors of Brucella spp., to characterize the host immune response, and to evaluate
therapeutics and vaccines. Other animal species have been used as models for brucellosis including rats, guinea pigs, and monkeys.
This paper discusses the murine and other laboratory animal models for human and animal brucellosis.
1. Introduction
Brucellosis is an infectious disease caused by bacteria of
the genus Brucella that affects humans as well as domestic
and wild animals, leading to significant impact on public
health and animal industry. Brucella spp. is a Gram-
negative, facultative intracellular bacterium that is able
to survive and replicate in phagocytic and nonphagocytic
cells, establishing a chronic infection in both humans and
animals [1]. Human brucellosis is considered the most
prevalent bacterial zoonosis in the world, with more than
500,000 new reported cases in humans each year, mainly
in Mediterranean countries, Central Asia, Arabic Peninsula,
India, and Latin America [2]. The disease is characterized
by nonspecific symptoms, including undulant fever, weight
loss, depression, hepatomegaly, and splenomegaly. Arthritis,
spondylitis, osteomyelitis, epididymitis, and orchitis, as well
as other more severe complications as neurobrucellosis, liver
abscesses, and endocarditis, are also commonly described in
patients [1, 2].
There are currently 8 recognized species of Brucella, of
which six are known to be capable of infecting humans.
Brucella melitensis, B. abortus, B. suis, and B. canis are
considered important zoonotic agents, and each one has
a domestic animal as preferential host: small ruminants,
bovines, swine, and dogs, respectively. Humans also can be
infected by two Brucella species recently isolated frommarine
mammals, B. ceti and B. pinnipedialis, and by B. inopinata,
the new species isolated in breast implant and lung biopsy
from human [3–5]. In domestic animals, Brucella colonize
the reticuloendothelial system and genital organs causing
chronic infection and reproductive disease characterized by
abortion, stillbirth, orchitis, epididymitis, and infertility,
resulting in significant economic losses [3, 6].
Relevant aspects of Brucella pathogenesis have been
intensively investigated in both cellular and animal models.
The mouse is the animal model most extensively used to
study chronic infection caused by Brucella spp. Moreover,
a few other animal species have been used as models for
brucellosis. This paper discusses well-characterized murine
models of brucellosis as well as other laboratory animal
models that have been used to study infection and disease
caused by Brucella spp.
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2. Murine Models for Human and
Animal Brucellosis
The mouse is often used as an animal model to investigate
the pathogenesis of human and animal brucellosis [7–9]. In
addition, the murine models are widely employed to test
antimicrobial drugs for treating the disease in humans [10–
12]. Availability of new molecular tools allowed the use of
murine models for identification of specific pathogenic fac-
tors of Brucella spp. and the characterization of host immune
response. As a result, control methods are being improved
and new vaccine candidates are being developed [8, 9, 13].
2.1. Mouse Strain-Specific Differences in Brucella Infection.
Several early studies using the mouse model demonstrated
that all of the mouse strains tested could be infected by B.
abortus, suggesting a lack of genetic loci in mice that deter-
mine complete resistance to B. abortus infection. A compari-
son of susceptibility of different strains of mice to B. abortus
strain 19 demonstrated susceptibility of CBA/H, BALB/c, or
C57BL/10 to B. abortus infection [14]. A subsequent study
comparing B. abortus infection in CD-1, BALB/cByJ, CBA/NJ
(containing the X-linked immunodeficiency trait), C3H/HeJ
(deficient in TLR4), and C3H/HeN mice found similar
colonization levels between all mouse strains, with a trend
for higher colonization of BALB/cByJ mice over a 12-week
time course [15]. A higher level of B. abortus colonization
in the BALB/cByJ strain was demonstrated definitively by
comparison with C57BL/10 mice, a mouse strain that is
closely related with the commonly used C57BL/6 strain
[16, 17]. More detailed studies have demonstrated that
an increased Th1 polarization of the immune response in
the C57BL strains is responsible for their more resistant
phenotype (see below for a more detailed discussion).
However, it should be kept in mind that most of these
comparative studies were performed using B. abortus, so that
it is possible that the susceptibility toward infection or the
infection kinetics may differ for other Brucella species.
Several mouse strains have been used to characterize
suitable murine models to study Brucella sp. infection. Four-
to 9-week-old BALB/c female mice are often used to evaluate
systemic distribution of Brucella sp. during the course of
infection [7, 17, 18]. Additionally, this animal model has
been used to study gene expression during Brucella sp.
infection, leading to the identification of several host genes
associated with innate and adaptive immune responses that
are activated during the course of infection [8, 19, 20]. Previ-
ous studies have shown that a high production of interferon-
gamma (IFN-γ) and interleukin 12 (IL-12) may lead to
efficient control of Brucella spp. infection in the mouse
model, due to activation of macrophages and induction of
natural killer cells and Th1 cellular response [8, 21, 22]. High
serum levels of both IFN-γ and IL-12 are also described in
humans during Brucella sp. infection, which is associated
with the induction of a Th1 response at early stages of
infection [23–25]. Additionally, natural killer (NK) cells
play an important role in controlling intracellular bacterial
infections, due to their ability to kill infected cells and secrete
IFN-γ. NK cells have a deficient cytotoxic activity in patients
with acute brucellosis, although these cells show normal
activity in treated patients [26]. However, it seems that NK
cells are not required to control B. abortus early infection
in the mouse, since mice with nonfunctional NK cells have
similar bacterial load when compared to immunocompetent
mice [27].Moreover, previous studies have shown that CD8+
T cells may also play a role against Brucella sp. persistent
infection [28–30]. In BALB/c mice, in vivo depletion of
CD8+ T cells leads to increased bacterial load in the spleen
[30]. In humans, peripheral blood CD8+ T cells that are
stimulated with heat-killed B. abortus or lipopolysaccharide
produce IFN-γ, which elicit a Th1 immune response [29].
C57BL/6 and C57BL/10 mice strains have also been used
to evaluate Brucella sp. infection, since they are consid-
ered more resistant to Brucella sp. infection than BALB/c
mice [16, 17, 22]. Comparative studies among these mice
strains helped detecting specific mechanisms of C57BL mice
immune response that are defective in BALB/c mice. These
mechanisms are likely important for controlling Brucella sp.
infection [8, 17, 22]. Additionally, various knockout mice
were developed by using C57BL/6 or 129/Sv as background
mice. The results obtained in this model seem to have high
similarity to host-pathogen interaction mechanisms that
were previously described in humans and domestic animals
[8, 31, 32]. Moreover, knockout mice with defective produc-
tion of cytokines related to innate immune response illustrate
the crucial role of specific cytokines against Brucella sp.
infection in hosts [22, 33, 34]. Interestingly, interferon reg-
ulatory factor-1-deficient (IRF-1−/−) mice infected with B.
abortus developed an acute hepatitis similar to humans but,
unlike the natural hosts, IRF-1−/− mice are unable to control
the infection and die within a short period of time. While
uncontrolled infection and death are not typical endpoints
of Brucella infection, the IRF-1−/− knockout mouse has been
useful for identifying and comparing residual virulence of
highly attenuated Brucella vaccine candidates [33].
2.2. Routes of Infection. Brucella infection may occur by
digestive route, inhalation or through nasal mucosa or
conjunctiva [6, 9]. After crossing the mucosal barrier,
the organisms reach regional lymph nodes, replicate in
macrophages, and establish a systemic and persistent infec-
tion. A bacteremic phase of infection results in colonization
of the spleen, liver, and osteoarticular tissues, and depending
on the Brucella species and host, it may also colonize the
mammary gland and the reproductive system [6, 9, 35].
In murine models of Brucella sp. infection, experimental
inoculation is performed mostly through three routes:
intraperitoneal, digestive, or nasal (aerosol).
The intraperitoneal route of infection is frequently used
to establish a persistent infection in the mouse, as it results
in a rapid systemic distribution of Brucella sp. and high
bacterial loads in the spleen and liver [7, 8, 18]. Initially,
Brucella multiplies during the first week, progressing to
a slow decrease in bacterial numbers at systemic sites of
infection. During the first 5 to 6 weeks after inoculation,
C57BL/6 or BALB/c mice infected with 106 CFU of B.
abortus strain 19 remain with stable numbers of organisms
at systemic sites of infection, and bacteria can be isolated
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up to two months after infection. However, B. abortus strain
2308 infection in BALB/c mice may persist over 6 months
[7, 36]. Murine models of intraperitoneal infection with
Brucella sp. allow the identification of pathogenic factors that
are required for establishment of chronic infection [37, 38].
For instance, comparison between input and output loads of
wild-type and mutant strains of Brucella in mouse models
resulted in the identification of pathogenic factors, including
the role of the type IV secretion system encoded by the
virB operon during Brucella sp. persistent infection in vivo
[31, 32, 38, 39]. virB mutant strains of Brucella sp. are
not capable of surviving and replicating intracellularly in
macrophages and, therefore, are attenuated in mouse models
in vivo [37–39].
The digestive tract is the main route of Brucella infec-
tion in humans, which is associated with the ingestion
of unpasteurized milk and dairy products from infected
animals [2, 40]. Murine models of intestinal infection allow
the identification of bacterial pathogenic factors that are
required to establish infection through the digestive tract
[41–44]. Recently, Paixa˜o and colleagues described a murine
model for intestinal infection of B. melitensis, in which a high
intragastric dose (∼1010 CFU per animal) leads to a systemic
infection in BALB/cByJ mice, probably due to bacterial
translocation through the intestinal mucosa via M cells [44].
Interestingly, this high infectious dose did not result in
intestinal inflammation in the mouse. Previous studies have
shown that mice can control intestinal Brucella infection
when they are previously vaccinated through the same route
[13, 45, 46]. Pasquali and colleagues demonstrated that
BALB/c mice previously treated with sodium bicarbonate
to neutralize gastric acid are more susceptible to B. abortus
systemic infection by digestive route than untreated mice
[46]. This result suggests that gastric acidity may interfere
with Brucella sp. However, a previous work has shown
that Brucella sp. challenge through the digestive tract is an
inadequate method to produce a uniform and consistent
infection in mice [47]. Additionally, it is important to
consider experimental issues in murine models, including
artificial inoculation using intragastric gavages and gastric
acid neutralization, which may significantly differ from Bru-
cella sp. natural infection in humans and animals. Bacterial
factorsmediating intestinal infection by Brucella sp. and their
target molecules at mucosal surfaces of the digestive tract
are still poorly understood; so additional studies evaluating
carefully this route are required.
Human brucellosis may also be acquired by inhalation.
The number of organisms required to establish the infection
in humans by this route is low, with an estimated infectious
dose of 10 to 100 organisms for humans by aerosol [48].
Therefore, Brucella sp. is considered a potential biological
warfare agent [49]. Characterization of murine models for
Brucella sp. infection by the nasal route (aerosol) may be
used to evaluate vaccines candidates and therapeutics for
human brucellosis [19, 50, 51]. A recent study demonstrated
that BALB/c female mice immunized with B. melitensis
attenuated strain Rev1 followed by aerosol infection with 104
CFU of B. melitensis 16M had a decreased bacterial load in
the spleen, suggesting that this animal is a suitable model to
Figure 1: Spleen of BALB/c mouse at 21 days of infection by
Brucella melitensis. The mouse was intragastrically infected with 105
CFU of B. melitensis 16M. Microgranulomas in red pulp (arrows).
HE. Bar: 100 μm.
evaluate protection during Brucella sp. aerosol infection [51].
Mice infection by aerosol with 106 CFU of B. melitensis or
107 CFU of B. abortus resulted in high bacterial load in the
spleen, liver, and lungs. However, infection doses as low as
102 and 103 CFU per animal are also sufficient to establish a
systemic infection in the mouse [19, 52, 53]. Apparently the
lung is only affected in the mouse during aerosol infection
with pathogenic species of Brucella. No histopathological
lesions have been described in the lung, but high bacterial
loads are recovered from the lungs at early time points during
infection, which indicates that Brucella sp. is able to replicate
in this organ without eliciting innate immune responses
[19, 52]. Although aerosol chambers have been effectively
used to study bacterial infections in mouse models [19], it
is important to consider that the infection dose that reaches
the lung of a mouse may be significantly lower than expected
[53]. Additionally, Brucella sp. infection in these models may
be established due to coinfection through the conjunctiva or
oral mucosa, since it was previously shown that bacteria can
be detected also in the fur of infected mice [19]. Therefore,
it is essential to critically evaluate the results of Brucella sp.
aerosol infection during vaccine studies in murine models.
An open question in the field is the identity of the Brucella
factors that are important for its efficient infection of the
respiratory tract.
2.3. Histopathological Changes during Brucella Infection.
During Brucella sp. infection in the mouse, the spleen is
the most heavily colonized organ, and it develops histiocytic
infiltrates and multifocal microgranulomas (Figure 1) [7, 18,
54]. BALB/c mice intraperitoneally (i.p.) infected with B.
abortus or B. melitensis develop significant splenomegaly,
which is more prominent than in mice infected by aerosol
(Figure 2) [19, 54]. The liver is also an important site
for colonization and replication of Brucella sp. in the
mouse [7, 13, 19]. Usually, mice infected with virulent
strains of Brucella sp. have mild to moderate hepatitis,
which is characterized by neutrophilic infiltrate at early
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Figure 2: BALB/c mouse i.p. infected with 106 CFU of Brucella ovis
ATCC25840 with severe splenomegaly at 30 days of infection.
stages of infection, followed by histiocytic infiltrate with
epithelioid cells and microgranulomas at chronic stages of
infection (Figure 3) with bacteria localizing intracellularly in
macrophages within microgranulomatous lesions (Figure 4)
[7, 54]. It is noteworthy that Brucella infection inmice results
in lesions that mimic those described in chronic infections
in humans. Patients with chronic brucellosis may develop
splenomegaly and hepatomegaly. Additionally, multifocal
granulomas with epithelioid macrophages are observed in
the parenchyma of the liver and spleen in biopsy samples
from infected patients [55, 56]. However, hepatic and splenic
abscess were described as uncommon complication in some
patients during the acute phase of Brucella sp. infection [57].
Brucella sp. chronic infection in humans may also lead to
osteoarticular disease, including osteoarthritis, spondliytis,
and osteomyelitis [1, 2]. A previous study [58] reported that
mice may develop bacterial colonization in osteoarticular
tissues during chronic stages of B. melitensis infection. In
IRF-1−/− mice that survived more than 45 days after i.p.
infection with 107 CFU of B. melitensis, a high number (∼
105 CFU) of bioluminescent B. melitensis were detected in
vertebral joints in the tail, suggesting that these mice might
be a useful model for the study of human osteoarticular
disease. However, a comparison of actual osteoarticular
lesions inmice and humans would help to assess the potential
utility of this model to study a common clinical presentation
of brucellosis in man.
2.4. Evaluation of Therapeutic Interventions and Vaccines.
The efficiency of different chemotherapies for human bru-
cellosis has also been evaluated in the mouse model [10,
11, 59]. The recommended treatment for human brucellosis
is a combination of rifampicin and doxycycline daily for at
least six weeks [60]. However, other antibiotic combinations
have been tested in animal models and infected patients.
Previous studies showed that mice infected with B. melitensis
and treated with ciprofloxacin, by subcutaneous (40mg/kg),
digestive (200mg/kg), or intraperitoneal (20mg/kg) route,
are not able to control the infection [10, 12], whereas
mice treated with doxycycline (40mg/kg) at 24 hours after
Figure 3: Liver of BALB/c mouse at 30 days of infection by
Brucella ovis. The mouse was i.p. infected with 106 CFU of Bru-
cella ovis ATCC25840. Microgranuloma containing predominantly
macrophages and neutrophils (arrow). HE. Bar: 100 μm.
Figure 4: Liver of BALB/c mouse at 30 days of infection by
Brucella ovis. The mouse was i.p. infected with 106 CFU of Brucella
ovis ATCC25840. Microgranuloma with immunolabelled B. ovis in
macrophages (arrow). IHC. Bar: 100 μm.
infection efficiently clear the infection [12]. Additionally,
Shasha and coworkers [10] reported that mice treated
with rifampin (25mg/kg) or doxycycline (40mg/kg) by
intraperitoneal route had high levels of antibiotics in the
blood (rifampin: 18 μg/ml; doxycycline: 5.4 μg/ml) and were
able to clear the infection. Moreover, new antibiotic carriers,
like microspheres, have been tested against Brucella sp.
infection. Microspheres are phagocytized by monocytes,
allowing direct access of the antibiotic to the intracellular
site of bacterial replication. However, a previous study
showed that mice infected with B. abortus and treated with
gentamicinmicrospheres (100 μg/animal) for three days were
not able to reduce bacterial load in the spleen after 1 and 3
weeks after treatment [11].
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Additionally, the quality of live vaccines that are commer-
cially used for preventing animal brucellosis is evaluated in
murine models [61]. Live B. abortus S19 strain, which is the
most widely used vaccine in cattle, has been tested in female
CD1 mice 5 to 7 weeks old. Mice are previously treated with
105 CFU of B. abortus reference vaccine (strain S19), a com-
mercial vaccine sample or PBS. After 30 days of vaccination,
all mice are i.p. infected with 105 CFU of B. abortus virulent
strain. Then, bacterial loads in the spleen are evaluated in
each group at 15 days after infection. A commercial vaccine
is considered efficient when mice have significantly lower
bacterial load than the unvaccinated control group and when
the vaccinated group has similar immunogenicity value to
mice group vaccinated with S19 reference strain [61].
2.5. Pathogenesis of the Reproductive Tract. Furthermore,
murine models were developed to study reproductive
changes described in human and animal brucellosis. Pre-
vious studies evaluated the occurrence of abortion and
placental colonization in female pregnant mice during B.
abortus infection [3, 35]. Although B. abortus infection is
not characterized by abortion in women [2], it is extremely
relevant to study Brucella pathogenesis in pregnant female
models, due to its significant economic impact in cattle
production as well as in other domestic animal species.
Moreover, uterine secretion and products from abortion are
the most important source of infection within a herd main-
taining the disease and may also represent an occupational
source of infection to humans [6, 35].
Previous studies from Bosseray characterized the infec-
tion in pregnant CD1 mice with B. abortus strain 544. The
infection did not lead to abortion or fetus death at early
stages of pregnancy, although high colonization of placenta
was described when mice were infected at 7 and 11 days of
pregnancy. Additionally, placental and splenic colonization
increased with higher challenge accordance to the infection
dose and each placenta was considered an independent unit,
as some placentas were colonized and others were not in the
same uterus [62]. Another study demonstrated the congeni-
tal infection of B. abortus in themouse at 7 days of pregnancy,
which resulted in the colonization of 60% of newborns. In
this study, newborns remained infected until 30 days and no
significant difference of Brucella sp. infection was observed
betweenmale and female newborns [63].Moreover, Bosseray
described the kinetics of placental colonization in mice
that were intravenously infected with B. abortus at 15 days
of pregnancy. Although low bacterial loads were recovered
from the placenta at early stages of infection (4–6 hours),
apparently local bacterial replication resulted in higher
colonization in the placenta at 72 hours after infection [64].
BALB/c female pregnant mice infected with 106 CFU of
B. abortus virulent strain 2308 develop amoderate multifocal
necrotic placentitis associated with severe neutrophilic infil-
trate and intralesional bacteria in trophoblastic cells [54].
The bacterial load and lesions described in the placenta
increase throughout the pregnancy, whereas the bacterial
load recovered from the spleen was stable during the course
of infection in the mouse [54, 65]. The lesions described
in female pregnant mice were similar to those observed
in cows, which suggests that this model may be useful to
study Brucella-induced placental disease, although mice and
cattle have different morphological types of placenta [54].
Additionally, Kim and colleagues [65] demonstrated that B.
abortus infection may lead to 98% of abortion in female
mice at 4.5 days of pregnancy. However, intraperitoneal
inoculation of the pathogen at any other time point during
the pregnancy does not result in a high abortion rate
although placentas from both aborted and live fetuses have
intracellular Brucella sp. in trophoblast giant cells. In natural
hosts, B. abortus infection leads to abortion in cows at
late stages of pregnancy due to placental lesions, which are
related to bacterial invasion and intracellular replication in
trophoblastic cells [66, 67].
Considering that male genital tract may also be affected
during Brucella sp. infection, male mice were characterized
to study specific bacterial mechanisms that lead to orchitis
and epididymitis in men and animals [3, 6]. Previous studies
reported that Brucella sp. may colonize the male genital tract
in the mouse [13, 58]. Izadjoo and colleagues demonstrated
that B. melitensis infection (1010 CFU) through the digestive
tract in sexually mature BALB/c male mice leads to perivas-
cular inflammation of the testes and histiocytosis in inguinal
lymph nodes [13]. In addition, use of male mice may be
important for testing residual pathogenicity of candidates
for vaccine strains, by evaluating histopathologic lesions in
the genital tract and the immune response against Brucella
sp. [13]. Recently, our laboratory developed a male mouse
model for Brucella ovis infection (Silva et al., unpublished
data). Although B. ovis is one of the few classical Brucella
species that do not have zoonotic potential, this organism
is considered a major cause of reproductive failure in sheep,
which leads to significant economic losses in the sheep indus-
try [68]. The characterization of a murine model has allowed
the study of pathogenic mechanisms used by B. ovis that may
determine the bacterial genital tropism in sexually mature
rams, causing epididymitis and orchitis exclusively in this
animal. Interestingly, B. ovis infection in male mice resulted
in early colonization of testes, epididymides, and semi-
nal vesicle. However, colonization of these organs quickly
decreased at later time points, and the inflammatory lesions
were restricted to peripheral tissues of the genital tract.
Therefore, male mice were not considered a good model for
B. ovis genital disease in rams, although it may be used as a
suitable infection model (Silva et al., unpublished data).
3. Other Laboratory Animal Models
for Brucellosis
Although the mouse is by far the most often used animal
model for brucellosis, it is a good animal model for chronic
infection of the reticulo-endothelial system but fails to
replicate some features of the clinical disease caused by
Brucella in humans, such as fever. Therefore, there are several
reports of experimental work employing other laboratory
animals, including rats, guinea pigs, and monkeys that are
susceptible to experimental infection with Brucella spp.
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3.1. Rodent Models Other Than Mice. The rat has been used
as a model for human brucellosis due to some peculiarities
of this species. Despite the fact that rats do not develop
physical signs of infection and are considered more resistant
to infection than mice, they develop persistent bacteremia
and do not have spontaneous cure after one month of
infection [69, 70]. Therefore, rats have been selected as an
experimental model for evaluation of increased susceptibility
to infection (including Brucella infection) in patients with
chronic disorders. Wistar Albino rats with diabetes were used
to evaluate the course of infection by B. melitensis. In this
case, diabetes is induced by streptozotocin before challenge
with B. melitensis. Diabetic rats have higher numbers of
bacteria in the liver and spleen when compared to control
rats [69]. Other studies investigated the effect of chronic
ethanol consumption on the course of B. melitensis infection
in a rat model [71–73]. Rats chronically treated with ethanol
have an increased susceptibility to B. melitensis due to a
decrease in protective cellular immunity [72]. The rat model
has also been used to study the efficacy of various antibiotics
for treating Brucella infection [74–76]. Sprague Dawley rats
were used to evaluate the efficacy of spiramycin, a macrolide
antibiotic, for treating brucellosis, since this drug has no
teratogenic effect, and therefore it is safe for pregnant women
[74]. Similarly to mice, rats are also used to study clinical and
pathological effects of B. abortus infection during pregnancy.
B. abortus did not affect pregnancy in Sprague Dawley
rats, paralleling what happens in women, although necrosis
in the periplacentomal chorionic epithelium and metritis
were observed in this model [77]. Although rats do not
abort even with placentitis, a previous study demonstrated
significant protection against systemic B. abortus infection
in rats vaccinated with RB51, a vaccine strain against bovine
brucellosis [78].
Guinea pigs are probably the most susceptible laboratory
animal species to Brucella infection. Early comparative
studies of susceptibility in guinea pigs, mice, rats, and sheep
demonstrated that guinea pigs developed granulomatous
lesions when inoculated with 10 CFU of B. melitensis or
B. suis [79]. Lesions were consistently observed in the liver,
spleen, lungs, and lymph nodes, resembling those described
in humans [80]. Guinea pigs inoculated subcutaneously with
infectious doses of B. abortus, B. suis, or B. melitensis develop
a persistent bacteremia for 6 weeks after infection, whereas
the attenuated B. abortus S19 is cleared from the blood at one
week after infection [81]. Therefore, the guinea pig model
may be considered valuable for the evaluation of candidate
vaccine strains [82, 83]. All classic Brucella species were
pathogenic for guinea pigs [70]. Furthermore, the guinea
pig has been employed as an animal model for evaluating
the efficacy of antibiotics and chemotherapeutic agents for
treatment of brucellosis [84, 85].
Although the rabbit is a laboratory animal frequently
used as an experimental model, it is not considered a
model of choice for Brucella infection. Rabbits are partially
susceptible to Brucella infection [70], and only about 20%
of infected animals developed a very short and sporadic
bacteremia with B. abortus or B. suis [86]. The pregnancy
increases systemic susceptibility of rabbits to B. abortus
infection but nevertheless the infecting organism was not
recovered from the uterus of pregnant female rabbits [70].
Hamsters (Syrian or Golden Hamster) do not appear to be
a good animal model for B. abortus infection, due the vast
individual differences in susceptibility [70].
3.2. Nonhuman PrimateModels. Nonhuman primatemodels
of Brucella infection have been reported in Macaca arctoides
and rhesus macaque (Macaca mulatta) infected with B.
abortus, B. melitensis, B. suis, and B. canis [87–90]. These
animals are susceptible to Brucella organisms administered
by digestive, subcutaneous, or respiratory routes and develop
persistent bacteremia up to eight weeks after inoculation
[89]. The primate infection leads to a multiple-organ
disease causing focal granulomatous hepatitis, splenitis,
and lymphadenitis, similar to human brucellosis [91]. In
a few cases, there is an involvement of the reproductive
tract causing granulomatous orchitis, epididymitis, or acute
endometritis [89]. Aerosol infection of nonhuman primates
has been reported [89, 90], resulting in a number of
pathologic changes similar to human brucellosis, suggesting
that nonhuman primatemodel is a suitablemodel for human
brucellosis [90]. It is noteworthy that the aerosol exposure
might possibly occur as a result of a bioterrorism event,
and studies of dose-dependent infection by this route and
animal model are important. Mense and colleagues [89]
reported that uninfected macaques, not inoculated with
Brucella organisms, became infected when housed in the
same room with inoculated macaques, suggesting that the
macaque is a good model to study Brucella infection by
aerosol route. Moreover, studies on the efficacy of diagnostic
methods for Brucella detection after aerosol exposure has
been performed, and therefore nonhuman primates could
provide an excellent model for testing of diagnostics [90].
4. Conclusions
Human brucellosis results in highly variable clinical man-
ifestations that are not quite paralleled by experimental
infections in laboratory animals. However, animal models,
particularly the mouse, have been extensively used and
allowed for accumulation of valuable information mostly in
the past recent years regarding the pathogenesis, immunity,
and antibiotic susceptibility of Brucella spp. in vivo. New
technologies in mouse genetics will likely bring about even
greater insights into the interaction of Brucella spp. with the
immune system that lead to disease in humans and in the
natural zoonotic reservoir hosts.
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